Funder: National Institutes of Health
Due Dates: October 21, 2025 (Renewal/Resubmission) | December 9, 2025 (Current closing date)
Funding Amounts: Up to $400,000 in direct costs per year (federal share); 1:1 non-federal matching required; max project period 2 years.
Summary: Supports renewal preclinical studies in regenerative medicine using adult stem cells (not embryonic/fetal), focused on advancing safe and effective therapies.
Key Information: Only current RMIP awardees under RFA-HL-18-030 or RFA-HL-23-019 are eligible; strict 1:1 matching requirement.